Octocog alfa
Key facts
| Invented name |
Advate
|
| Active substance |
octocog alfa
|
| Therapeutic area |
Haematology-Hemostaseology
|
| Decision number |
P/65/2010
|
| PIP number |
Octocog alfa
|
| Pharmaceutical form(s) |
Powder and solvent for solution for injection
|
| Condition(s) / indication(s) |
Haemophilia A (congenital Factor VIII deficiency)
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Baxter AG
E-mail: juliana_brankova@baxter.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|